20212-67-3

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 6138-90-5 trans-geranyl bromide 

Downstream Products

• 1219966-99-0 1-{3-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-hydroxy-4-(methoxymethoxy)phenyl}ethanone 
• 791113-30-9 2'-hydroxy-3'-geranyl-4'-benzyloxyacetophenone 
• 791113-14-9 4-chloro-2',4'-dihydroxy-3'-geranylchalcone 

Relevant academic research and scientific papers

DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR

The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R1 represents a hydrogen atom, R2 represents an alkyl group containing 1 to 7 carbon atoms, R3 represents -CHO, and R4 represents -CH2-CH=C(CH3)-R0 (wherein R0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti-H. pylori agent, a therapeutic agent for diabetes or the like.

NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents -CHO, -C(=O)R5, -COOR5 (wherein R5 represents a C1-7 alkyl group), -CH2OH or -COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.

New synthetic routes to biologically interesting geranylated flavanones and geranylated chalcones: First total synthesis of (±)-prostratol F, xanthoangelol, and (±)-lespeol

A new and efficient synthetic approach to biologically interesting geranylated flavanones and geranylated chalcones is described. Thus, the first total syntheses of the geranylated flavanones (±)-prostratol F (1), (±)-8-geranyl-3′,4′,7-trihydroxyflavanone (2), and (±)-6-geranyl-5,7-dihydroxy-3′,4′-dimethoxyflavanone (3) were carried out starting from 2,4-dihydroxyacetophenone (10) and 2,4,6-trihydroxyacethophenone (17) in five to six steps (Schemes 2 and 3). The geranylated chalcones xanthoangelol (4), 3-geranyl-2,3′,4,4′- tetrahydroxychalcone (5), (±)-lespeol (6), and lespeol derivatives (±)-7-9 were synthesized starting from 2,4-dihydroxyacetophenone (10) in three to four steps (Schemes 2 and 6).

THERAPEUTIC AGENT

A therapeutic agent and prophylactic agent for a disease accompanying an abnormality in an amount of insulin or insulin response, an agent for an insulin-mimetic action, a food, beverage and feed, an agent for enhancing glucose uptake into a cell, and an agent for inducing differentiation into an adipocyte, characterized in that each comprises as an effective ingredient at least one compound selected from the group consisting of a chalcone compound, an acetophenone compound, a coumarin compound, a phthalide compound, derivatives thereof, and pharmacologically acceptable salts thereof.